Paradigm Health has simultaneously activated its Study Conduct platform for clinical trials with Amgen, a US biotech, and AstraZeneca, the Anglo-Swedish pharmaceutical giant.1 No prior operational track record exists. Both Phase 1b and Phase 2 trials are now running on an untested system.
Study Conduct ingests electronic health records in real time, applying automated classification across live trial data streams. Each link in that chain carries a distinct failure mode—and the global clinical trial industry has seen all of them before.
EHR integration outages are the most immediate threat. Disconnections between hospital systems and the platform create data gaps. Regulators worldwide—including the FDA, the European Medicines Agency, and Japan's PMDA—treat unexplained gaps as missing data. That finding can invalidate safety signals or efficacy endpoints entirely.
Algorithmic misclassification is a second vector. Automated systems that miscategorize adverse events or patient eligibility distort outcomes without immediate alerts. Phase 1b and Phase 2 trials use small patient populations. A single misclassification carries outsized statistical weight.
Data ingestion errors compound both risks. If raw data fails to load correctly at the source, all downstream analysis reflects corrupted inputs. Post-hoc reconciliation is difficult and may not satisfy FDA data integrity standards—or equivalent requirements under ICH guidelines used across the EU, UK, and Asia-Pacific.
Running Amgen and AstraZeneca trials in parallel amplifies exposure significantly.1 Errors affecting both sponsors concurrently would open parallel liability tracks across multiple jurisdictions and draw simultaneous regulatory scrutiny. Smaller platforms have historically failed under that pressure.
The FDA relationship adds a second layer of risk. Real-time regulatory review is Paradigm Health's core value proposition globally. Early operational failures that degrade data quality could prompt regulators to reassess whether the platform meets oversight standards—slowing AI adoption in clinical trials more broadly, well beyond the US market.
EHR integration failures have derailed multiple trial platforms internationally before they reached commercial scale. Paradigm Health's launch window—high-stakes, multi-sponsor, with live regulatory data—leaves limited margin for the operational errors common in early deployments.
How the company manages this period will determine whether Study Conduct builds durable trust with pharma partners and regulators worldwide, or faces a credibility crisis before it reaches scale.
